TWI815907B - 麥角硫因、抗壞血酸2-葡萄糖苷、抗壞血酸、及該等的組合的肌肉分化促進作用 - Google Patents

麥角硫因、抗壞血酸2-葡萄糖苷、抗壞血酸、及該等的組合的肌肉分化促進作用 Download PDF

Info

Publication number
TWI815907B
TWI815907B TW108120402A TW108120402A TWI815907B TW I815907 B TWI815907 B TW I815907B TW 108120402 A TW108120402 A TW 108120402A TW 108120402 A TW108120402 A TW 108120402A TW I815907 B TWI815907 B TW I815907B
Authority
TW
Taiwan
Prior art keywords
ascorbic acid
muscle
differentiation
egt
cells
Prior art date
Application number
TW108120402A
Other languages
English (en)
Chinese (zh)
Other versions
TW202015549A (zh
Inventor
小坂邦男
Original Assignee
日商長瀨產業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商長瀨產業股份有限公司 filed Critical 日商長瀨產業股份有限公司
Publication of TW202015549A publication Critical patent/TW202015549A/zh
Application granted granted Critical
Publication of TWI815907B publication Critical patent/TWI815907B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pediatric Medicine (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW108120402A 2018-06-29 2019-06-13 麥角硫因、抗壞血酸2-葡萄糖苷、抗壞血酸、及該等的組合的肌肉分化促進作用 TWI815907B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-124613 2018-06-29
JP2018124613 2018-06-29

Publications (2)

Publication Number Publication Date
TW202015549A TW202015549A (zh) 2020-05-01
TWI815907B true TWI815907B (zh) 2023-09-21

Family

ID=68986429

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108120402A TWI815907B (zh) 2018-06-29 2019-06-13 麥角硫因、抗壞血酸2-葡萄糖苷、抗壞血酸、及該等的組合的肌肉分化促進作用

Country Status (6)

Country Link
US (1) US12454678B2 (enExample)
EP (1) EP3816278A4 (enExample)
JP (3) JP7759724B2 (enExample)
CN (1) CN112352046A (enExample)
TW (1) TWI815907B (enExample)
WO (1) WO2020004014A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022230487A1 (enExample) * 2021-04-26 2022-11-03
WO2022242711A1 (en) * 2021-05-20 2022-11-24 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Methods for ameliorating and preventing age‐related muscle degeneration
JP7569818B2 (ja) * 2022-03-11 2024-10-18 キッコーマン株式会社 エルゴチオネインを光に対し安定化させた液体組成物
JPWO2024172003A1 (enExample) * 2023-02-16 2024-08-22
DE102023131771B3 (de) 2023-09-15 2025-02-06 Esspen Gmbh Verfahren und Vorrichtung zur Verarbeitung medizintechnischer Bilddaten im Zusammenhang mit einer Trepanation
WO2026148341A1 (en) * 2025-01-06 2026-07-09 Mironova Labs, Inc ʟ-ERGOTHIONEINE COCRYSTAL AND DERIVATIVES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099277A1 (en) * 2002-05-20 2003-12-04 Oxis International, Inc. Method of reducing incidence diabetic embryopathy with l-ergothioneine
CN101496774A (zh) * 2007-11-30 2009-08-05 Lvmh研究所 包含抗坏血酸2-葡糖苷和麦角硫因的美容组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100227307A1 (en) 2007-04-12 2010-09-09 Hausman Marvin S Ergothioneine and/or its derivatives as a cell preservative
US20110262965A1 (en) * 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
US20120141611A1 (en) * 2010-12-05 2012-06-07 Oxis International Inc. Methods and compositions using ergothioneine to treat a variety of health related factors
CA2877861A1 (en) * 2012-06-26 2014-01-03 Entia Biosciences, Inc. A nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2
TWI549696B (zh) 2014-09-05 2016-09-21 中國醫藥大學 麥角硫因應用於活化細胞之Ｎｒｆ２訊息途徑之用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099277A1 (en) * 2002-05-20 2003-12-04 Oxis International, Inc. Method of reducing incidence diabetic embryopathy with l-ergothioneine
CN101496774A (zh) * 2007-11-30 2009-08-05 Lvmh研究所 包含抗坏血酸2-葡糖苷和麦角硫因的美容组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Y Mitsumoto 1, Z Liu, A Klip , "A long-lasting vitamin C derivative, ascorbic acid 2-phosphate, increases myogenin gene expression and promotes differentiation in L6 muscle cells", Biochem Biophys Res Commun 199(1) 1994 Feb 28 394-402 *
期刊 林作慶 麥角硫因對高齡大鼠劇烈運動引起之氧化壓力及骨骼肌損傷的機能影響 嘉大體育健康休閒期刊 15卷2期 2016/08/31 P110-122; *

Also Published As

Publication number Publication date
JP2025148417A (ja) 2025-10-07
EP3816278A4 (en) 2022-05-04
US20210130787A1 (en) 2021-05-06
US12454678B2 (en) 2025-10-28
CN112352046A (zh) 2021-02-09
TW202015549A (zh) 2020-05-01
JP7759724B2 (ja) 2025-10-24
WO2020004014A1 (ja) 2020-01-02
JPWO2020004014A1 (ja) 2021-07-15
EP3816278A1 (en) 2021-05-05
JP2024026241A (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
JP7759724B2 (ja) エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用
CN112672749A (zh) 具有肥胖预防或治疗效果的新的长双歧杆菌菌株或鼠李糖乳杆菌菌株及其用途
JP7013238B2 (ja) 筋脂肪化抑制用組成物
TWI830696B (zh) 抑制肌纖維變性用組成物
CN109963574B (zh) 用于预防或治疗肝纤维化的包含脂肪干细胞来源外排体作为活性成分的组合物
JP6209579B2 (ja) 補助化療薬品とされる医薬組成物その用途
US20190038769A1 (en) Micro-rna profiling, compositions, and methods of treating diseases
TW201813656A (zh) 用於使時鐘基因之表現變化的組合物
US20180071248A1 (en) Composition for improving circadian rhythm
JP6157928B2 (ja) 肝臓への脂肪蓄積抑制剤
JP6716330B2 (ja) ウロプラキン発現促進剤
KR102187681B1 (ko) 히알루론산 나노입자를 함유하는 섬유증의 예방 또는 치료용 약학 조성물
US11414663B2 (en) Micro-RNA profiling, compositions, and methods of treating diseases
KR20190018795A (ko) 마이크로 RNA-30a 및 RNA-30b를 유효성분으로 함유하는 방사선 치료 민감제 조성물
US12606824B2 (en) Micro-RNA profiling, compositions, and methods of treating diseases
JP5930507B2 (ja) ヒアルロン酸産生促進剤
JP2014015428A (ja) サテライト細胞分化促進剤
HK40089668A (en) Composition containing sesamin or like and nr and/or nmn
WO2022085603A1 (ja) 筋量増加、筋力増加、筋量減少抑制又は筋力低下抑制用組成物
JP5923404B2 (ja) Ｔｒｐｖ４活性抑制剤
WO2022244758A1 (ja) ケトン供与体を含む組成物
JP6168485B2 (ja) ヒアルロン酸産生促進剤
CN118215493A (zh) 胰功能活化剂、抗老化剂、2型糖尿病的治疗药或预防药、药品、化妆品和食品或饮料
WO2022085602A1 (ja) Ｔｇｒ５活性化用組成物
CN113940929A (zh) 维拉帕米在制备促使骨代谢进入低转换以防治骨质疏松的产品中的应用